Acceptance Limits for the New ICH USP 29 Content-Uniformity Test - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Acceptance Limits for the New ICH USP 29 Content-Uniformity Test
Revisions to the United States Pharmacopeia's (USP) uniformity test require manufacturers to establish new acceptance limits. The authors present their method for calculating acceptance limits consistent with USP's revised content-uniformity test requirements.


Pharmaceutical Technology


References

1. United States Pharmacopeia, "‹905› Uniformity of Dosage Units," Pharmacopeial Forum 32 (6), 1653–1659, 2006.

2. Statistics Working Group of PhRMA, "Content Uniformity: Evaluation of the USP Pharmacopeial Preview," Pharmacopeial Forum 24 (5), 7029–7044, 1998.

3. Statistics Working Group of PhRMA, "Content Uniformity: Alternative to the USP Pharmacopeial Preview," Pharmacopeial Forum 25 (2), 7939–7948, 1999.

4. Statistics Working Group of PhRMA, "Recommendations for a Globally Harmonized Uniformity of Dosage Units Test," Pharmacopeial Forum , 25 (4), 8609–8624, 1999.

5. J.S. Bergum, "Constructing Acceptance Limits for Multiple Stage Tests," Drug Dev. Ind. Pharm. 16 (14), 2153–2166, 1990.

6. J.S. Bergum and M.L. Utter, "Process Validation," in Encyclopedia of Biopharmaceutical Statistics, S.C. Chow, Ed., (Marcel Dekker, New York, 2000), pp. 422–439.

7. J.S. Bergum and M.L. Utter, "Statistical Methods for Uniformity and Dissolution Testing" in Pharmaceutical Process Validation, Robert A. Nash and Alfred H. Watchter, Eds., (Marcel Dekker, New York, 2003), pp. 667–697.

8. J. S. Bergum's SAS Programs, Content Uniformity and Dissolution Acceptance Limits (CUDAL), version: 1.0, validation completed 02/11/02.

9. J.B. Berman et al., "Blend Uniformity Analysis: Validation and in-process testing," Technical Report No. 25, PDA J. Pharm. Sci. Technol. (suppl.) 51, 1997.

10. B.W. Lindgren, "Normal Populations" in Statistical Theory, C. B. Allendoerfer, (Macmillan, New York,1968), 390–391.

11. F.A. Graybill and C.M. Wang, "Confidence Intervals on Nonnegative Linear Combination of Variances," J. Am. Stat. Assoc. 75 (372), 869–873, 1980.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here